Groupe :

Secteur :

Activité principale :

Oxeltis, founded in Montpellier (France) in 2010, is a medicinal chemistry service provider for biotech, pharmaceutical companies, and research institutions.

The company has a small-scale custom synthesis business, as well as hit and lead optimization services, mainly in the areas of antivirals, antibiotics and anticancer compounds with expertise in heterocyclic chemistry, macrocycles, nucleosides/nucleotides, modified sugars and oligo/polysaccharides.

Produits et services :

Savoir-faire

The company has a small-scale custom synthesis business, as well as hit and lead optimization services, mainly in the areas of antivirals, antibiotics and anticancer compounds.

Atouts

The Oxeltis team comprises 18 experienced medicinal chemists (12 PhD, 6 MSc) with expertise in particular areas of organic synthesis: heterocyclic chemistry, macrocycles, nucleosides/nucleotides, modified sugars and oligo/polysaccharides. The team focuses on speed, quality and confidentiality in the services and collaborative ventures that it develops.

Principales réalisations

Oxeltis works with European and North American start-up and big pharma companies as well as research institutions. Several lead candidates developed with our clients are currently in clinical trial development.